CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS muta...
Phase 1
San Antonio, Texas, United States and 22 other locations
and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic...
Phase 1
San Antonio, Texas, United States of America and 17 other locations
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with...
Phase 1, Phase 2
San Antonio, Texas, United States of America and 11 other locations
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 ef...
Phase 1
San Antonio, Texas, United States and 1 other location
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
San Antonio, Texas, United States and 16 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....
Phase 1
San Antonio, Texas, United States and 14 other locations
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors...
Phase 1, Phase 2
San Antonio, Texas, United States and 2 other locations
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemipl...
Phase 1, Phase 2
San Antonio, Texas, United States and 12 other locations
dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors...
Phase 1, Phase 2
San Antonio, Texas, United States and 3 other locations
administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are ...
Phase 1
San Antonio, Texas, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal